82 completed, 23 terminated, 15 recruiting, 8 unknown. 57 Phase 1, 49 Phase 2, 15 Phase 3, 13 Not applicable, 4 Early Phase 1.
Follow Leukemia, Large Granular Lymphocytic: new trials by email Literature Review of Leukemia, Large Granular Lymphocytic trials Research Report on Leukemia, Large Granular Lymphocytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-09-30 | 2026-07-06 |
| A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia zeprumetostat - Large Granular Lymphocyte Leukemia, T-LGL Leukemia | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-08-30 | 2026-09-21 |
| Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia | Recruiting | Rong Tao | 1500 | 2026-08-11 | 2026-08-13 | |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas PI3K inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 51 | 2024-08-10 | 2025-08-12 |
| Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia Thalidomide and methotrexate - T-LGL Leukemia, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-08-10 | 2025-11-18 |
| Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia PPMX-T003 - Aggressive NK Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Hiroshima University Hospital | 7 | 2023-09-21 | 2025-04-30 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Ruxolitinib - T-Cell Large Granular Lymphocyte Leukemia | Phase 2 | Recruiting | Jonathan Brammer | 30 | 2023-05-03 | 2026-10-01 |
| Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia Anti-CD56 CAR T - Extranodal NK T Cell Lymphoma, NK-Cell Leukemia | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2023-05-01 | 2023-07-12 |
| Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) Siltuximab - Large Granular Lymphocyte Leukemia | Early Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2023-02-15 | 2026-02-05 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) ABC008 - T-cell Large Granular Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Abcuro, Inc. | 21 | 2022-09-28 | 2026-05-06 |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas DR-01 - LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dren Bio | 200 | 2022-07-13 | 2026-06-17 |
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia | Phase 1 / Phase 2 | Active not recruiting | Jonathan Brammer | 11 | 2022-06-29 | 2026-10-21 |
| Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors KT-333 - Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Completed | Kymera Therapeutics, Inc. | 56 | 2022-05-19 | 2025-03-19 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2021-08-12 | 2026-09-09 |
| National Longitudinal Cohort of Hematological Diseases Multiple Myeloma, Acute Myeloid Leukemia | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2300 | 2020-12-01 | 2026-02-12 | |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Methotrexate, pralatraxate,, Ifosfamide - NK-Cell Lymphoma, NK-Cell Leukemia | Early Phase 1 | Recruiting | New York Medical College | 40 | 2019-03-01 | 2026-08-18 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Cyclophosphamide, Fludarabine, Thiotepa - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 69 | 2019-01-31 | 2026-09-15 |
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL BNZ132-1-40 - LGL Leukemia, CTCL | Phase 1 / Phase 2 | Completed | Bioniz Therapeutics | 50 | 2018-04-01 | 2021-05-25 |
Showing 20 of 142. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (107) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (100) · Lymphoma, Follicular (93) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (92) · Lymphoma, Large-Cell, Anaplastic (91) · Lymphoma, Mantle-Cell (91) · Lymphoma, T-Cell, Cutaneous (91) · Lymphoma, Non-Hodgkin (90) · Mycosis Fungoides (90) · Immunoblastic Lymphadenopathy (89) · Leukemia, Hairy Cell (89) · Lymphoma, B-Cell, Marginal Zone (89) · Lymphoma, Large B-Cell, Diffuse (89) · Sezary Syndrome (89)
Hemic and Lymphatic Diseases (142) · Immune System Diseases (142) · Immunoproliferative Disorders (142) · Lymphatic Diseases (142) · Neoplasms by Histologic Type (142) · Hematologic Diseases (141) · Leukemia, T-Cell (141) · Leukemia, Lymphoid (139) · Neoplasms (127) · Lymphoproliferative Disorders (120) · Pathologic Processes (112) · Pathological Conditions, Signs and Symptoms (112) · Disease Attributes (111) · Chronic Disease (108) · Leukemia, B-Cell (108)
Peripheral Blood Stem Cell Transplantation (17) · fludarabine phosphate (16) · Cyclophosphamide (14) · Cyclosporine (13) · Mycophenolic Acid (11) · Whole-Body Irradiation (11) · Etoposide (7) · Methotrexate (6) · Antilymphocyte Serum (5) · Filgrastim (5) · Tacrolimus (5) · Alemtuzumab (4) · Bortezomib (4) · Busulfan (4) · Melphalan (4)
National Cancer Institute (NCI) (16) · Fred Hutchinson Cancer Center (11) · Institute of Hematology & Blood Diseases Hospital, China (7) · Case Comprehensive Cancer Center (6) · M.D. Anderson Cancer Center (6) · Northwestern University (5) · Barbara Ann Karmanos Cancer Institute (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Jonsson Comprehensive Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Alliance for Clinical Trials in Oncology (3) · City of Hope Medical Center (3) · German CLL Study Group (3) · UNC Lineberger Comprehensive Cancer Center (3) · University of Medicine and Dentistry of New Jersey (3)
United States (113) · Germany (12) · Italy (11) · China (9) · France (6) · Switzerland (5) · Belgium (4) · Canada (4) · Slovakia (3) · Spain (3) · Turkey (Türkiye) (3) · Australia (2) · Israel (2) · South Korea (2) · Austria (1)
Brenda Sandmaier (3) · John A. Glaspy, MD, MPH (3) · Abhinav Deol, M.D. (2) · Ann Woolfrey (2) · David Maloney (2) · Elisabeth Paietta, PhD (2) · Jonathan Brammer, MD (2) · Jorge Cortes, MD (2) · Mohamed Sorror (2) · Richard K. Burt, MD (2) · Ryotaro Nakamura (2) · Shuhua Yi, Doctor (2) · Tapan Kadia, MD (2) · Adam J. Esbenshade, MD (1) · Adam Petrich, MD (1)
PMID 32499241, PMID 15459300, PMID 16710026, PMID 17020988, PMID 17119113, PMID 17397698, PMID 18327587, PMID 18698002, PMID 19170225, PMID 19841031, PMID 19900571, PMID 22259028, PMID 22480131, PMID 23212516, PMID 23358983, PMID 23512246, PMID 24474568, PMID 26175532, PMID 26213141, PMID 26659919, PMID 26700120, PMID 26700123, PMID 26765645, PMID 26853648, PMID 27020837, PMID 28054442, PMID 29292843, PMID 30205939, PMID 30562587, PMID 31617432, PMID 31689242, PMID 34806163, PMID 35489026, PMID 36448227, PMID 36647781, PMID 37352612, PMID 37358640, PMID 37534514, PMID 37680953, PMID 37846845, PMID 37870698, PMID 37967471, PMID 38170583, PMID 38249329, PMID 38505288, PMID 39095502, PMID 40069155, PMID 40353947, PMID 40588385, PMID 41657941
P30CA015704 (10), P01CA018029 (5), P30CA016672 (4), P30CA043703 (4), P30CA072720 (4), U01CA097452 (3), N01CM62202 (2), P30CA015083 (2), P30CA016086 (2), P30CA022453 (2), P30CA033572 (2), P30CA068485 (2), U01CA062502 (2), U01CA062505 (2), U10CA032102 (2)